Inve India ▾

Solara Active Pharma Sciences share price & results

Solara Active Pharma Sciences Limited· Healthcare

Results to
Sept 2026
Latest analysed call
Q2 FY27
Ownership as of
Sept 2026

Pure-play API manufacturer supplying 60+ pharma ingredients to 70+ countries from 6 Indian plants.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue417 ₹ crore+32.8% YoYQuarterly, as filedQuarter to Sept 2026Revenue from operations as filed.
Operating margin18.0 %+7.0 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit28.0 ₹ crore—Quarterly, as filedQuarter to Sept 2026Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.
Return on equity3.27 %−0.2 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin7.38 %−6.1 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)27.28 %+7.0 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Sept 2026

Guidance

What management said, and what became of it

3 of 9 judged targets kept · 13 open · verdicts reflect calls analysed to Q2 FY27.

Solara Active Pharma Sciences Limited management guidance track record on Inve: 22 targets tracked across analysed earnings calls (3 achieved, 6 missed, 13 open).

TargetOriginal wordingSaidLatest callVerdict
Deferred Sales RecoveryService the business in next two quarters (Q3/Q4)
Call transcript, Q2 FY26 · 5 Nov 2025		Q2 FY26Q2 FY27:Promise was achieved in Q3 FY26. No further updates.
Call transcript, Q2 FY27 · 23 Oct 2026		Achieved
FY26 Revenue Growtharound 10%
Call transcript, Q1 FY26 · 25 Jul 2025		Q1 FY26Q2 FY27:The promise pertains to the completed FY26 period and remains missed. No further updates.
Call transcript, Q2 FY27 · 23 Oct 2026		Missed
CRAMS Equity Infusion PlanMore answers... in the next call
Call transcript, Q1 FY26 · 25 Jul 2025		Q1 FY26Q2 FY27:Despite promising an update with Q2 results, no CRAMS plan was announced as the overarching Ibuprofen strategic review was pushed out by an additional 12 weeks.
Call transcript, Q2 FY27 · 23 Oct 2026		Delayed

Source: Inve Guidance Tracker for Solara Active Pharma Sciences Limited · to Q2 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

6 of Solara Active Pharma Sciences Limited's 22 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 19 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹636.7 +0.34% · +₹2.15

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +7.7% 1Y

₹400₹500₹600₹700Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 4 Nov 2025Q3 FY26 — 10 Feb 2026Q4 FY26 — 15 May 2026Q1 FY27 — 23 Jul 2026Q2 FY27 — 23 Oct 2026

1Y: ₹591.15 on 24 Oct 2025 → ₹636.7. High ₹753.25 (21 Sept 2026), low ₹425.55 (30 Mar 2026).

Previous close
₹634.55
Market cap
₹3.0k Cr
52-week range
₹425.55 – ₹753.25
One year
+7.74%
Price to earnings (TTM to Sept 2026)
63.15×
Return on equity (TTM to Sept 2026)
3.27%

Overview

Symbol
NSE:SOLARA
Exchange
NSE
Currency
INR

What Solara Active Pharma Sciences Limited does

Based on the company's own presentations, annual report and earnings calls.

Solara Active Pharma Sciences is a pure-play manufacturer of Active Pharmaceutical Ingredients (APIs), offering a diversified portfolio of over 60 commercial APIs across therapeutic areas such as pain management, anti-infectives, anti-malarials, anti-convulsants and anti-psychotics to customers in more than 70 countries. It operates six API manufacturing facilities across India (Ambernath, Mysuru, Mangaluru, Vizag, Puducherry and Cuddalore) with a combined reactor capacity of 2,673 KL, alongside a dedicated research and innovation centre in Chennai. Its plants carry approvals from major global regulators including the USFDA, EU GMP, WHO and Japan's PMDA. The company earns revenue by manufacturing and selling APIs and pharmaceutical intermediates to formulators worldwide, and internally splits its business into a regulated-markets 'base' API portfolio and a separate, currently commodity-priced Ibuprofen business.

Segments

  • Base API business
  • Commodity Ibuprofen business
API manufacturing facilities
6 (across India)
Countries served
70+
Commercial API portfolio
60+ commercial APIs, with 10 more under active development
Total reactor capacity
2,673 KL
Cumulative USFDA audits completed
33 (across sites, to date)
R&D scientists
60+
Headquarters Chennai, Tamil Nadu, India Company website

How the price took the results

close before → close after

Q2 FY27
−1.2%
23 Oct
Q1 FY27
−2.3%
23 Jul
Q4 FY26
+14.2%
15 May
Q3 FY26
+2.4%
10 Feb

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Solara Active Pharma Sciences Limited

Free account: one company. Everything above stays public.

Write why you follow Solara Active Pharma Sciences Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Solara Active Pharma Sciences Limited

Guides on how to read this kind of business and the numbers that matter.